Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT05035953
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT05035953
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05035953. Randomized; double masking; primary purpose treatment. Start 2021-09-13 (anticipated); primary completion 2023-09-13 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke
- Condition
- Stroke, Ischemic
- Intervention (Drug)
- Edaravone Dexborneol
- Intervention (Drug)
- Placebo
- Lead sponsor
- Huashan Hospital
- Collaborator
- Shanghai Stroke Association
Record details
- Record id
cardio:ct-nct05035953- Content hash
86a4d8aab556b8d5b4d2c8dcd407b4248abc724a409f2ba6827186c2a82823b9